Physician profile
Michael Fastenberg
NPI 1073735593
$357,232.51
in general payments reported to CMS, 2019-2025
46 companies · $67K in 2025
The $67K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $52K · 2021: $53K · 2022: $28K · 2023: $65K · 2024: $57K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110K · Consulting Fee: $57K · Food and Beverage: $20K · Travel and Lodging: $1,506 · Education: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,425.00 |
| Consulting Fee | $57,212.50 |
| Food and Beverage | $19,868.68 |
| Travel and Lodging | $1,505.82 |
| Education | $412.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $81,419.66 | 2019-2025 | Aklief, Twyneo, Oracea |
| Amgen INC. | $71,905.82 | 2020-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $68,917.96 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $40,931.21 | 2020-2021 | |
| Pfizer INC. | $23,392.12 | 2019-2025 | |
| Verrica Pharmaceuticals INC. | $12,718.36 | 2023-2025 | Ycanth |
| Celgene Corporation | $12,195.36 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11,353.22 | 2025 | Zoryve |
| Leo Pharma INC. | $8,073.33 | 2019-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $3,763.14 | 2019-2025 | |
| Dermavant Sciences, INC. | $3,638.76 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $2,608.97 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $2,584.80 | 2019-2025 | |
| Medimetriks Pharmaceuticals, INC. | $2,037.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,675.29 | 2019-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,076.79 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $1,016.71 | 2020-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $955.55 | 2021-2025 | Opzelura |
| Genzyme Corporation | $848.13 | 2019-2025 | |
| Almirall LLC | $828.85 | 2019-2025 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $782.70 | 2019-2025 | Dupixent, Libtayo |
| Epi Health, LLC | $598.84 | 2019-2022 | |
| Biofrontera INC. | $587.73 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Ucb, INC. | $582.62 | 2021-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $491.61 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $449.19 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| E.R. Squibb & Sons, L.L.C. | $296.61 | 2022-2024 | Sotyktu |
| Allergan, INC. | $252.79 | 2019-2021 | |
| Organon LLC | $161.45 | 2025 | Vtama |
| Dermira, INC. | $159.50 | 2019-2020 | |
| Encore Dermatology INC. | $115.14 | 2019 | |
| Paratek Pharmaceuticals, INC. | $110.37 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.42 | 2022-2024 | Spevigo |
| Nabriva Therapeutics, Plc | $88.11 | 2021-2022 | |
| Sandoz INC. | $87.67 | 2019 | |
| Botanix Sb INC | $84.46 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Lnhc, INC | $43.91 | 2025 | Zelsuvmi |
| Dusa Pharmaceuticals, INC. | $40.10 | 2019 | |
| Organogenesis INC. | $39.52 | 2025 | Puraply Wound Matrix |
| Mission Pharmacal Company | $34.97 | 2020-2021 | |
| Genentech USA, INC. | $32.15 | 2019 | |
| Promius Pharma LLC | $25.07 | 2019 | |
| Sebela Pharmaceuticals INC. | $23.87 | 2023 | Naftin, Pramosone |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Merck Sharp & Dohme LLC | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fastenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.